Artificial Intelligence in Medical Technology Myths and Facts
Artificial intelligence (AI) and its subset, machine learning (ML), are expanding in multiple applications, including medical technology. Outlining the facts and dispelling myths will inform policymaking to avoid overlap with current regulations and preserve the broad capacity of innovation to help patients.
Related Reading
Event / Regulatory Affairs
Accelerating Medtech Innovation Through AI-Enabled Product Development
June 24, 2026
12:00 PM – 1:00 PM
Join Kearney as they explore how medtech organizations are using AI to transform product development and accelerate innovation.
Event / Regulatory Affairs
Accelerating ASC Transition and Medtech Commercial Model Imperatives
July 21, 2026
11:00 AM – 12:00 PM
Explore ASC growth trends, buyer dynamics & go-to-market strategies for medtech manufacturers in this webinar with Alexander Group.
Resource / Diagnostics / Regulatory Affairs
Clinical Evidence for IVD Medical Devices
May 22, 2026
AdvaMed’s feedback on the CEIVD draft outlines targeted recommendations to improve clarity in clinical evidence expectations for IVD devices, including more precise terminology, alignment with global frameworks, and clearer distinctions between real-world data and evidence.
News / Regulatory Affairs
AdvaMed® Welcomes Senate Introduction of Bipartisan Medical Device Electronic Labeling Bill
May 14, 2026
Washington, D.C.—AdvaMed, the Medtech Association, the world’s biggest trade association representing medtech innovators, welcomed Senate introduction of the bipartisan Medical Device Electronic Labeling Act (S. 4519), which would allow medtech instructions for use to be provided electronically, with paper copies being available upon request.
News / Regulatory Affairs / Small Business
Bright Uro Receives FDA Clearance for Glean® Abdominal Sensor
May 8, 2026
IRVINE, Calif., May 7, 2026 /PRNewswire/ — Bright Uro, a medical device company with a mission to transform care for lower urinary tract dysfunction (LUTD) through innovations in urodynamics, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Glean® Abdominal Sensor. This new sensor expands the capabilities of the Glean® Urodynamics System to include multi-channel urodynamic studies. This comprehensive system enables wireless, catheter-free ambulatory urodynamics designed to support clinical decision making for patients with LUTD and other urological conditions.
News / Regulatory Affairs
i-GENTIC AI Expands GENIE to Enforce Full FDA Compliance Lifecycle for Life Sciences
May 4, 2026
PALO ALTO, CA, UNITED STATES, May 4, 2026 / EINPresswire.com / — Biopharma and medtech companies face a years-long process to get their products approved. Drug and device makers navigate a full spectrum of FDA and global regulatory frameworks to move innovation forward.
Blog / Coverage & Payment / Government & Legislative Affairs / Health Access / Regulatory Affairs
A Policy Win for Maternal Health Innovation Through FDA–CMS Collaboration
April 27, 2026
The United States faces a maternal health crisis demanding urgent action. The U.S. has the worst maternal outcomes among high income nations. Our maternal mortality rates far exceed peer countries’, despite the highest per capita health care spending. Protecting mothers and improving birth outcomes provides an important opportunity for bipartisan priority leadership.
Event / Regulatory Affairs
Compliance Considerations in an Active Deals Market for Medtech
June 17, 2026
11:00 AM – 12:00 PM
Join PwC to explore how compliance leaders can proactively support deal activity across the transaction lifecycle.
